Targeting FOXM1 in cancer

Biochem Pharmacol. 2013 Mar 1;85(5):644-652. doi: 10.1016/j.bcp.2012.10.013. Epub 2012 Oct 24.


Oncogenic transcription factor FOXM1 is overexpressed in the majority of human cancers. In addition, FOXM1 has been implicated in cell migration, invasion, angiogenesis and metastasis. The important role of FOXM1 in cancer affirms its significance for therapeutic intervention. Current data suggest that targeting FOXM1 in mono- or combination therapy may have promising therapeutic benefits for the treatment of cancer. However, challenges with the delivery of anti-FOXM1 siRNA to tumors and the absence of small molecules, which specifically inhibit FOXM1, are delaying the development of FOXM1 inhibitors as feasible anticancer drugs. In this review, we describe and summarize the efforts that have been made to target FOXM1 in cancer and the consequences of FOXM1 suppression in human cancer cells.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / classification
  • Antineoplastic Agents / therapeutic use*
  • Drug Design
  • Forkhead Box Protein M1
  • Forkhead Transcription Factors / antagonists & inhibitors*
  • Forkhead Transcription Factors / genetics
  • Forkhead Transcription Factors / metabolism*
  • Gene Expression Regulation, Neoplastic / physiology*
  • Humans
  • Neoplasms / metabolism
  • Neoplasms / therapy*
  • RNA Interference


  • Antineoplastic Agents
  • FOXM1 protein, human
  • Forkhead Box Protein M1
  • Forkhead Transcription Factors